Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

Xenon announced it will outline upcoming milestones at the 2026 J.P. Morgan Healthcare Conference. The press release includes a Safe Harbor statement noting that forward-looking statements involve risks and uncertainties.

Xenon Pharmaceuticals issued a press release titled "Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference." The release indicates the company will discuss upcoming milestones at the 2026 J.P. Morgan Healthcare Conference. The document includes a detailed Safe Harbor statement referencing U.S. and Canadian securities laws. The company also notes that the Xenon name and logo are registered trademarks. What the release states: - Xenon and the Xenon logo are registered trademarks in the United States, Canada, and elsewhere. - The press release contains forward-looking statements as defined under the U.S. Securities Act and Exchange Act and under Canadian securities laws. - Examples of subjects mentioned as forward-looking include timing and potential results of clinical studies; potential efficacy and safety profiles; future development plans for azetukalner and other pipeline programs; anticipated filings of INDs and NDAs; timing of any NDA submission; and timing of topline data readouts. - The release lists a range of risks and uncertainties that could cause actual results to differ, including clinical study results, regulatory interactions, funding and economic conditions, competition, and other factors. - The forward-looking statements are described as speaking only as of the date of the release, and the company states it assumes no obligation to update them. Summary: The press release signals Xenon's intention to outline upcoming development milestones at the 2026 J.P. Morgan Healthcare Conference while emphasizing that statements about timing, results, and regulatory plans are forward-looking and subject to risk. Undetermined at this time.